Casalia Mariana L, Howard MacKenzie A, Baraban Scott C
Epilepsy Research Laboratory, Department of Neurological Surgery and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
Ann Neurol. 2017 Oct;82(4):530-542. doi: 10.1002/ana.25021. Epub 2017 Oct 4.
A significant proportion of the more than 50 million people worldwide currently suffering with epilepsy are resistant to antiepileptic drugs (AEDs). As an alternative to AEDs, novel therapies based on cell transplantation offer an opportunity for long-lasting modification of epileptic circuits. To develop such a treatment requires careful preclinical studies in a chronic epilepsy model featuring unprovoked seizures, hippocampal histopathology, and behavioral comorbidities.
Transplantation of progenitor cells from embryonic medial or caudal ganglionic eminence (MGE, CGE) were made in a well-characterized mouse model of status epilepticus-induced epilepsy (systemic pilocarpine). Behavioral testing (handling and open field), continuous video-electroencephalographic (vEEG) monitoring, and slice electrophysiology outcomes were obtained up to 270 days after transplantation (DAT). Post-hoc immunohistochemistry was used to confirm cell identity.
MGE progenitors transplanted into the hippocampus of epileptic mice rescued handling and open field deficits starting at 60 DAT. In these same mice, an 84% to 88% reduction in seizure activity was observed between 180 and 210 DAT. Inhibitory postsynaptic current frequency, measured on pyramidal neurons in acute hippocampal slices at 270 DAT, was reduced in epileptic mice but restored to naïve levels in epileptic mice receiving MGE transplants. No reduction in seizure activity was observed in epileptic mice receiving intrahippocampal CGE progenitors.
Our findings demonstrate that transplanted MGE progenitors enhance functional GABA-mediated inhibition, reduce spontaneous seizure frequency, and rescue behavioral deficits in a chronic epileptic animal model more than 6 months after treatment. Ann Neurol 2017;82:530-542.
全球目前超过5000万癫痫患者中,有很大一部分对抗癫痫药物(AEDs)耐药。作为AEDs的替代疗法,基于细胞移植的新型疗法为持久改变癫痫环路提供了机会。要开发这样一种治疗方法,需要在具有自发性发作、海马组织病理学和行为共病特征的慢性癫痫模型中进行仔细的临床前研究。
将来自胚胎内侧或尾侧神经节隆起(MGE、CGE)的祖细胞移植到一个特征明确的癫痫持续状态诱导癫痫(全身性匹鲁卡品)小鼠模型中。在移植后长达270天(DAT)的时间里,进行行为测试(处理和旷场试验)、连续视频脑电图(vEEG)监测以及脑片电生理结果评估。事后免疫组织化学用于确认细胞身份。
移植到癫痫小鼠海马体中的MGE祖细胞从60 DAT开始挽救了处理和旷场试验缺陷。在这些相同的小鼠中,在180至210 DAT期间观察到癫痫发作活动减少了84%至88%。在270 DAT时,对急性海马脑片中的锥体神经元测量的抑制性突触后电流频率,在癫痫小鼠中降低,但在接受MGE移植的癫痫小鼠中恢复到未处理水平。在接受海马内CGE祖细胞移植的癫痫小鼠中未观察到癫痫发作活动减少。
我们的研究结果表明,移植的MGE祖细胞增强了功能性GABA介导的抑制作用,降低了自发性癫痫发作频率,并在治疗后6个月以上的慢性癫痫动物模型中挽救了行为缺陷。《神经病学纪事》2017年;82:530 - 542。